Chardan Capital Reiterates Buy on Rocket Pharmaceuticals, Maintains $61 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $61.

August 11, 2023 | 8:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rocket Pharmaceuticals has been reiterated with a 'Buy' rating by Chardan Capital, with a maintained price target of $61.
The reiteration of a 'Buy' rating by a financial analyst usually indicates a positive outlook for the company's stock. The maintained price target of $61 also suggests that the analyst believes the stock has potential for growth. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100